Method of modulating the proliferation of medullary thyroid carcinoma cells

• US 9,220,760 B2
• Filed: 05/02/2007
• Issued: 12/29/2015
• Est. Priority Date: 03/06/2001
• Status: Expired due to Fees

• Current Assignee: Administrators Of The Tulane Educational Fund (ADMINISTRATORS|DAVID H. COY), Ipsen Pharma Sas (Ipsen Sa), The University of Ferrara
• Original Assignee: Administrators Of The Tulane Educational Fund (ADMINISTRATORS|DAVID H. COY)
• Inventors: Coy, David H.
• Primary Examiner(s): Yu, Misook
• Assistant Examiner(s): Moseley, II, Nelson B
• Application Number:
  US11/799,594
• Publication Number:
  US 20070259811A1
• Time in Patent Office: 3,163 Days
• Field of Search: None
• US Class Current: 1/1
• CPC Class Codes: A61K 38/08 Peptides having 5 to 11 amino acids A61K38/043 - A61K38/046 take precedence
• CPC Class Codes: A61K 38/31 Somatostatins
• CPC Class Codes: A61P 35/00 Antineoplastic agents
• CPC Class Codes: A61P 35/04 specific for metastasis
• CPC Class Codes: A61P 43/00 Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
• CPC Class Codes: A61P 5/02 of the hypothalamic hormones, e.g. TRH, GnRH, CRH, GRH, somatostatin

Abstract

The present invention is directed to a method of decreasing the rate of proliferation of medullary thyroid carcinoma cells which comprises contacting medullary thyroid carcinoma cells with one or more SSTR2 agonist. A somatostatin receptor antagonist having the formula Cpa-cyclo(D-Cys-4-Pal-D-Trp-Lys-Thr-Cys)-Nal-NH₂ is also disclosed.

Claims

1. A somatostatin type-2 receptor antagonist comprising the formula Cpa-cyclo(D-Cys-4-Pal-D-Trp-Lys-Thr-Cys)-Nal-NH₂ (SEQ ID NO:

6) or a pharmaceutically acceptable salt thereof.